AstraZeneca Takes a More Personal Approach to Connecting with NEXIUM® (esomeprazole magnesium) Patients

    AstraZeneca Takes a More Personal Approach to Connecting with NEXIUM®
                      (esomeprazole magnesium) Patients

NEXIUM YouTube Channel Provides Information on Acid Reflux Disease, Symptom
Relief and Savings

PR Newswire

WILMINGTON, Del., July 15, 2013

WILMINGTON, Del., July 15, 2013 /PRNewswire/ --Acid reflux disease, also
known as gastroesophageal reflux disease (GERD), is one of the most common
chronic illnesses in the US today, affecting more than 60 million Americans
each month.^1 To help educate consumers about NEXIUM, a prescription treatment
option for those diagnosed with GERD, as well as support and empower those
living with the condition, AstraZeneca (NYSE: AZN) has launched resources
ranging from disease information to video and interactive content via the
NEXIUM® YouTube channel.

To view the multimedia assets associated with this release, please visit:
http://www.multivu.com/mnr/62163-astrazeneca-nexium-youtube-channel-acid-reflux-symptom-relief

"The majority of patients today use social media to source health and wellness
information," said Ken Graham, Commercial Business Leader, GI, AstraZeneca.
"With more than one billion unique users visiting YouTube each month, the
NEXIUM YouTube channel puts everything from background on GERD to information
on cost savings for NEXIUM at patients' fingertips."

By visiting the NEXIUM YouTube channel, patients can find:

  o"Burning thoughts" on controlling GERD symptoms: lifestyle or dietary
    changes that can go a long way in providing relief. New "burning thoughts"
    will be posted to the channel each week
  oEngaging videos on acid reflux disease and NEXIUM as a treatment option:
    informative visual content that provides background on the role of stomach
    acid in digesting food and how NEXIUM works by inhibiting proton pumps in
    the stomach. A second video overviews important safety information and
    indications for NEXIUM
  oRelief is at Hand "shareable" badge: a social way for patients to share
    information about NEXIUM with their friends and family. The badge is a way
    for patients to show their commitment to fighting GERD, and patients will
    be able to "pass the purple" with the badge on Facebook and Twitter

"For more than two decades, AstraZeneca has been a leader in developing
medications and educational resources for gastrointestinal diseases," said
Marta Illueca, Executive Director Medical Affairs and Strategic Development
for Cornerstone Brands. "The NEXIUM channel represents a new and innovative
way through which we're looking to reach and engage patients."

AstraZeneca in Gastrointestinal Diseases
Since the FDA first approved NEXIUM in 2001, it has been prescribed more than
236 million times.^2 The new tools for patients suffering from GERD build on
AstraZeneca's strong legacy and commitment to this therapeutic space.

About the NEXIUM Savings Card
It is simple to save on NEXIUM. With the NEXIUM Savings Card, most eligible
patients will pay just $18 per month. Individual out-of-pocket costs may vary.
Please see eligibility for details. Other restrictions may apply.

Important Safety Information About NEXIUM

  oSymptom relief does not rule out the presence of other serious stomach
    conditions
  oNEXIUM may increase your risk of getting severe diarrhea. Call your doctor
    right away if you have watery stool, stomach pain and fever that does not
    go away
  oTalk to your doctor about your risk for:

       obone fractures if you take multiple daily doses of NEXIUM for a long
         period of time
       olow magnesium levels if you take NEXIUM for a long period of time

  oTell your doctor about all of the medicines you take, prescription and
    non-prescription drugs, including clopidogrel, vitamins and herbal
    supplements. NEXIUM may affect how other medicines work and other
    medicines may affect how NEXIUM works.
  oSide effects with NEXIUM include headache, diarrhea, and abdominal pain

Approved Uses for NEXIUM
NEXIUM is prescribed to treat the symptoms of acid reflux disease, which
typically include persistent heartburn on 2 or more days per week, despite
treatment and change of diet.

For many people, NEXIUM is also prescribed to heal damage to the esophagus
called erosive esophagitis. This damage may be caused over time from stomach
acid wearing away the lining of the esophagus. Only a doctor can diagnose this
condition. With NEXIUM, most erosions heal in 4 to 8 weeks. Your results with
NEXIUM may vary.

Please see Prescribing Information.

Please see Medication Guide.

Visitwww.youtube.com/AZPurpleZoneor PurplePill.com for more information.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.FDA.gov/medwatchor call 1-800-FDA-1088.

NOTES TO EDITORS
GERD is the underlying cause of more than 18 million physician and hospital
visits, 3.1 million hospitalizations and over 1,000 deaths in the US.^3

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription
Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe
(292-6363).

NEXIUM and the color purple as applied to the capsule are registered
trademarks of the AstraZeneca group of companies.

AZ&Me is a trademark of the AstraZeneca group of companies. 

Media Inquiries:

Stephanie Andrzejewski +1 302 885 8896

References

1.American College of Gastroenterology. Acid Reflux. 2013. Accessed June 3,
    2013. http://patients.gi.org/topics/acid-reflux/.
2.IMS NPA database, last accessed July 2011.
3.Everhart JE, ed. The Burden of Digestive Diseases in the United States.
    Bethesda, MD: National Institute of Diabetes and Digestive and Kidney
    Diseases, U.S. Dept of Health and Human Services; 2008. NIH Publication
    09–6433.

SOURCE AstraZeneca

Website: http://www.astrazeneca-us.com